-
-
-
-
-
-
-
Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 5c ; Offers Guidance
-
-
-
-
-
-
-
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
-
-
-
-
-
-
-
Amneal Reports Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
Amneal Receives First Product Approval in China
-
-
-
-
-
-
-
Amneal Pharmaceuticals (AMRX) Submits Abbreviated NDA to FDA for Three Key Complex Generics
-
-
-
-
-
-
-
Amneal Pharmaceuticals (AMRX) Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
-
-
-
-
-
-
-
Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance
-
976,272 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All